ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MDST Medicsight

0.45
0.00 (0.00%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Medicsight LSE:MDST London Ordinary Share GB00B1YD4B09 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.45 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Medicsight Share Discussion Threads

Showing 151 to 174 of 550 messages
Chat Pages: Latest  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
31/3/2010
11:05
I got some yesterday @ 5.16 and 5.11. the 5.11 did not shown on the system.

CASH £10.5M, enough to last for up to 2 years.

rejawna
29/1/2010
20:59
Errr..... because they have a tendancy to lose plenty of it each year.
the big fella
29/1/2010
20:21
Why would you not buy as significantly below cash?????????????
red army
29/1/2010
17:09
Who are house-broker?

I'll continue to watch here. Might be a good chance to make some money!

stuart14
29/1/2010
16:34
There has been a determined seller all week in big volume,what troubles me is why KBC have suddenly dropped their price by 35%.
mikeja
29/1/2010
16:31
There isn't any volume so I guess nothing too sinister. MM's are getting nervous across AIM now, they are less and less prepared to hold stock.
stuart14
29/1/2010
16:21
Definitely,KBC on the offer at 3.75,smells really bad.Has the cash disappeared into thin air?
mikeja
29/1/2010
16:08
Hmmm. Somethings afoot!
stuart14
29/1/2010
16:05
I met someone recently who worked for them. He was made redundant along with most of the Sale team and Dev team I believe.
stuart14
29/1/2010
15:02
On the face of it they are cheap. However I have followed these since the old Radical Tech days on OFEX, and lets face it they have never failed to disappoint.
the big fella
29/1/2010
13:10
Edison put a NPV of £147m on the co a year ago but were expecting permissions by H1 2009.The current mkt cap is £8m and cash around £10m
mikeja
29/1/2010
13:00
Stuart,I guess they will roll it out themselves,all the machines are in place.
How do you know they made redundancies b4 Xmas?

mikeja
29/1/2010
09:34
I know they made a lot of redundancies before Christmas so overheads must be a lot lower now. I'd guess they'll get approval from the US or Japan and then look to sell up. What sort of price could they get?
stuart14
28/1/2010
07:21
At 6p they are valued at a discount to the cash and have tax losses of around £40m.Something may come out of Japan next month.If and when they get approval in both mkts,Edison has suggested they cld make £40m in the first yr,we will see,but it sure has been a long wait.
mikeja
26/1/2010
14:39
This is why - not sure why it's taken them 3 weeks to tell the market?


Additional Information request for FDA 510(k) Clearance of
ColonCAD software


Medicsight PLC (AIM: MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists radiologists in the
early detection of disease, announces that on 5 January 2010 it received a
further request for Additional Information (AI) letter from the US Food and Drug
Administration (FDA) relating to the Company's currently pending 510(k)
pre-market notification for the ColonCAD API 3.1 product.

spectoacc
26/1/2010
14:31
This is surely becomming very very cheap now.
stuart14
17/11/2009
12:23
Hoodless Brennan comment;

Medicsight (MDST, £17.9m), the Computer Aided Detection (CAD) and image analysis software business, reports Q3 results to 30 September 2009. Net revenues from external customers up 65% to £0.094m (Q309: £0.057m) and operating losses before interest and taxes are reduced to £6.6m (Q308: -£7.3m). The business is debt-free, with net cash of £12.3m (H109: £13.7m) at the end of September 2009. The group continues to reduce spend to preserve cash. Medicsight is still waiting for approval from the FDA and Japanese Ministry of Health, Labour and Welfare ("MHLW"). We are slightly concerned that the approvals are taking longer than usual. However, the strong balance sheet combined with the potential for FDA approval encourages us to retain our SPECULATIVE BUY.

philjeans
08/11/2009
04:34
Thanks a lot Damanko! Looks like a lot has happened over the years. I'll dig thru my paperwork and see what i can come up with lol.

Thanks again.

ST

shortermer
31/10/2009
14:53
Cheers for That damanko, More murkier than i had thought. I nearly got sucked into buying after reading Fryern's thread on Unq, entitled "Do you want to be a Millionaire" or something like. Thankfully I do not and a profit is all i hope for out of shares ;-).

regards.

tenapen
30/10/2009
16:44
Sorry but is this the old Radical Technology, from OFEX years ago, that underwent a reverse takeover or something? Newbies probably wouldn't recall but any long term shareholders here? Long term as in peeps who have held for over 4 years or so?

Thanks,

ST

shortermer
29/10/2009
20:40
This forgotten crock could just turn out to be the nuggett at the bottom of the bucket.
philjeans
29/10/2009
20:11
The '2009 European CT Colonography Company of the Year Award,' is presented to Medicsight for its exceptional performance demonstrated by the company's ColonCAD™, in the CT colonography [CTC] segment. With its decade long experience, Medicsight is an industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and identification of colorectal disease.

Originally, the company functioned as a R&D organisation, however over the last 2-3 years Medicsight has moved its focus to a more commercial nature by bringing the best of its products to market. The World Health Organisation (WHO) indicates that lung and colorectal cancers are one of the most prevalent cancers in western societies, and having had its cohesive focus on the CTC segment, Medicsight focused on the opportunities that were created in this space. With only one segment in its vicinity, Medicsight had significant resources to innovate and launch quality products under this category. As a result, Medicsight developed ColonCAD™, a leading software tool that improves the detection capabilities of CT colonography by meliorating the sensitivity and productivity of detecting polyps in the colon.

foret
29/10/2009
19:53
Medicsight receives Frost & Sullivan Award
foret
28/10/2009
09:37
Excellent news today from an independent survey in the US.

Will add credibility to the product.

philjeans
Chat Pages: Latest  10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock